JP2023510132A5 - - Google Patents
Info
- Publication number
- JP2023510132A5 JP2023510132A5 JP2022537812A JP2022537812A JP2023510132A5 JP 2023510132 A5 JP2023510132 A5 JP 2023510132A5 JP 2022537812 A JP2022537812 A JP 2022537812A JP 2022537812 A JP2022537812 A JP 2022537812A JP 2023510132 A5 JP2023510132 A5 JP 2023510132A5
- Authority
- JP
- Japan
- Prior art keywords
- kit according
- human
- cancer
- monoclonal antibody
- ilt4
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962951357P | 2019-12-20 | 2019-12-20 | |
| US62/951,357 | 2019-12-20 | ||
| PCT/US2020/065208 WO2021126906A1 (en) | 2019-12-20 | 2020-12-16 | Methods for treating cancer using a combination of a pd-1 antagonist, an ilt4 antagonist, and chemotherapeutic agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023510132A JP2023510132A (ja) | 2023-03-13 |
| JP2023510132A5 true JP2023510132A5 (enExample) | 2023-12-22 |
Family
ID=76476667
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022537812A Withdrawn JP2023510132A (ja) | 2019-12-20 | 2020-12-16 | Ｐｄ－１アンタゴニスト、ｉｌｔ４アンタゴニストおよび化学療法剤の組合せを使用して癌を治療する方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230050449A1 (enExample) |
| EP (1) | EP4076521A4 (enExample) |
| JP (1) | JP2023510132A (enExample) |
| KR (1) | KR20220123017A (enExample) |
| CN (1) | CN115087461A (enExample) |
| AU (1) | AU2020408678A1 (enExample) |
| BR (1) | BR112022012081A2 (enExample) |
| CA (1) | CA3162311A1 (enExample) |
| MX (1) | MX2022007516A (enExample) |
| WO (1) | WO2021126906A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250011453A1 (en) * | 2021-07-20 | 2025-01-09 | Merck Sharp & Dohme Llc | Methods for treating cancer using a combination of a pd-1 antagonist, an ilt4 antagonist, and chemotherapeutic agents |
| WO2024120526A1 (zh) * | 2022-12-09 | 2024-06-13 | 诺纳生物（苏州）有限公司 | 抗ilt4抗体及其制备方法和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015176033A1 (en) * | 2014-05-15 | 2015-11-19 | Bristol-Myers Squibb Company | Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent |
| EP3322731B1 (en) * | 2015-07-14 | 2021-01-13 | Bristol-Myers Squibb Company | Method of treating cancer using immune checkpoint inhibitor; antibody that binds to programmed death-1 receptor (pd-1) or programmed death ligand 1 (pd-l1) |
| TWI796329B (zh) * | 2017-04-07 | 2023-03-21 | 美商默沙東有限責任公司 | 抗－ilt4抗體及抗原結合片段 |
| TWI799432B (zh) * | 2017-07-27 | 2023-04-21 | 美商再生元醫藥公司 | 抗ctla-4抗體及其用途 |
| EA202091540A1 (ru) * | 2017-12-22 | 2021-03-22 | Джаунс Терапьютикс, Инк. | Антитела к lilrb2 |
| WO2019148410A1 (en) * | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Anti-pd-1 antibodies |
| SG11202007590TA (en) * | 2018-02-13 | 2020-09-29 | Merck Sharp & Dohme | Methods for treating cancer with anti-pd-1 antibodies |
| CN113056483B (zh) * | 2018-07-09 | 2025-08-01 | 戊瑞治疗有限公司 | 结合到ilt4的抗体 |
| AU2019343131A1 (en) * | 2018-09-17 | 2021-04-29 | Icahn School Of Medicine At Mount Sinai | Anti-LILRB2 antibodies and methods of use thereof |
| US20230058779A1 (en) * | 2020-01-02 | 2023-02-23 | Merck Sharp & Dohme Llc | Combination cancer treatment using a pd-1 antagonist, an ilt4 antagonist, and lenvatinib or salts thereof |
-
2020
- 2020-12-16 US US17/785,590 patent/US20230050449A1/en not_active Abandoned
- 2020-12-16 JP JP2022537812A patent/JP2023510132A/ja not_active Withdrawn
- 2020-12-16 CA CA3162311A patent/CA3162311A1/en active Pending
- 2020-12-16 KR KR1020227025207A patent/KR20220123017A/ko not_active Withdrawn
- 2020-12-16 BR BR112022012081A patent/BR112022012081A2/pt unknown
- 2020-12-16 WO PCT/US2020/065208 patent/WO2021126906A1/en not_active Ceased
- 2020-12-16 EP EP20902955.2A patent/EP4076521A4/en not_active Withdrawn
- 2020-12-16 CN CN202080097157.4A patent/CN115087461A/zh active Pending
- 2020-12-16 AU AU2020408678A patent/AU2020408678A1/en active Pending
- 2020-12-16 MX MX2022007516A patent/MX2022007516A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2749098T3 (es) | Anticuerpos ANTI-B7-H1 y ANTI-CTLA-4 para tratar el cáncer de pulmón no microcítico | |
| JP2020528750A5 (enExample) | ||
| JP2023113893A5 (enExample) | ||
| JP2021102627A5 (enExample) | ||
| JP2017533912A5 (enExample) | ||
| JP2015532292A5 (enExample) | ||
| IL295230A (en) | Combination therapy with anti-cd73 antibodies | |
| JP2017507900A5 (enExample) | ||
| JP2022548947A5 (enExample) | ||
| JP2019535254A5 (ja) | 抗ｐｄ−ｌ１抗体および変異型 | |
| JP2020504141A5 (enExample) | ||
| RU2017133273A (ru) | Ингибиторы pd-1 / pd-l1 для лечения рака | |
| JP2020508317A5 (enExample) | ||
| CN117442719A (zh) | 用于治疗肺癌的抗pd-1抗体 | |
| JP2020502271A5 (enExample) | ||
| JP2017522307A5 (enExample) | ||
| RU2008149918A (ru) | Антитела к nkg2a и их применения | |
| JP2014509593A5 (enExample) | ||
| RU2017126476A (ru) | Новые модуляторы и способы их применения | |
| RU2018111529A (ru) | Комбинированная терапия для лечения рака | |
| JP2018527383A5 (enExample) | ||
| JP2023515675A5 (enExample) | ||
| JP2019524714A5 (enExample) | ||
| JP2010520290A5 (enExample) | ||
| JP2023510199A5 (enExample) |